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Abstract: Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a 
cytoplasmic tyrosine kinase (TK) domain present on many solid tumors including non-small 
cell lung cancer (NSCLC). Once stimulated by ligand, the downstream pathway is activated 
leading to cell growth, survival, and carcinogenesis. There are several methods of EGFR inhibi-
tion including monoclonal antibodies directed against the external region and small molecule 
inhibitors of TK domain. Erlotinib and geﬁ  tinib are orally available small molecule EGFR TK 
inhibitors, with proven efﬁ  cacy in NSCLC. The most common side effects are skin toxicity and 
diarrhea. Erlotinib has been shown to improve survival compared to placebo in second or third-
line therapy for NSCLC. However, erlotinib in combination with chemotherapy failed to show 
a survival advantage in two ﬁ  rst-line studies which could be due to the timing of chemotherapy 
administration. In general, patients with adenocarcinoma histology, female gender, Asian ethnic-
ity, and never smokers have a better response when treated with erlotinib. This could be related 
to the presence of EGFR mutations, lack of KRAS mutations, or overexpression of EGFR as 
measured by ﬂ  uorescent in-situ hybridization (FISH) analysis. Future studies should concentrate 
on further development of predictors of clinical beneﬁ  t with erlotinib, overcoming resistance to 
erlotinib that develops in initial responders, as well as more effective sequencing of erlotinib 
with chemotherapy and combinations of the drug with other “targeted” therapeutic agents.
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Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) belongs to a family of four receptors: ErbB-1 
(EGFR), ErbB-2 (HER2/neu), ErbB-3 (HER3), and ErbB-4 (HER4) responsible for 
cell survival (Ciardiello and Tortora 2001). EGFR is a transmembrane receptor with 
an internal tyrosine kinase (TK) domain which is phosphorylated after the binding of 
the ligand to the receptor. The activation of this domain will then stimulate several 
internal signaling pathways which in turn affects cell proliferation, differentiation and 
survival (Herbst 2004). There is evidence to suggest that this process can promote 
cancer development and metastasis (Engebraaten et al 1993; Chan et al 1999).
There are several methods of inhibiting the EGFR pathway including monoclonal 
EGFR antibodies and small molecule inhibitors of TK. Cetuximab (Erbitux®; Imclone 
Systems Inc., Branchburg, NJ, USA) is a chimeric human/mouse monoclonal antibody 
directed against the extracellular domain of the EGFR and is approved for use in 
colorectal and head and neck cancer (Cunningham et al 2004; Saltz et al 2004; Bonner 
et al 2004). Cetuximab competitively blocks the binding of the EGF and other ligands 
to the EGFR thus preventing the activation of the downstream TK resulting in growth 
arrest and apoptosis (Gill et al 1984; Sato et al 1983; Baselga 2000). Another EGFR 
antibody is panitumomab (Vectibix®; Amgen, Thousand Oaks, CA, USA) which is 
fully humanized and approved for metastatic colorectal cancer. The use of EGFR 
targeted antibodies is under active investigation in lung cancer, but without proven 
efﬁ  cacy at this time.Biologics: Targets & Therapy 2007:1(4) 336
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A different method of blocking EGFR is by inhibiting the 
cytoplasmic TK domain. Geﬁ  tinib (Iressa®; AstraZenica Phar-
maceuticals, Wilmington, DE, USA) and erlotinib (Tarceva®; 
Genentech, So San Francisco, USA) are both orally available 
small molecule EGFR TK inhibitors. Geﬁ  tinib was initially 
approved in the United States based on encouraging response 
rate and survival in phase II studies (Fukuoka et al 2003; 
Kris et al 2003), but was subsequently pulled from the North 
American market when a randomized phase III trial (ISEL) 
failed to show a survival beneﬁ  t versus placebo (Thatcher 
et al 2005). Erlotinib, however, is currently approved for use 
as second-line or third-line therapy in patients with non-small 
cell lung cancer (NSCLC) based on the landmark BR.21 trial 
which showed a statistically signiﬁ  cant survival advantage for 
the drug versus placebo (Shepherd 2005), as well as in com-
bination with gemcitabine in locally advanced or metastatic 
pancreatic cancer (Moore et al 2007).
Erlotinib phase I trials
The initial phase I trial of erlotinib in solid tumors evaluated 
different doses (25, 50, 100, 150, 200 mg) and schedules (d1-
3 weekly for 3 weeks every 28 days; daily for 3 weeks every 
28 days; daily-uninterrupted) and found a maximum tolerated 
dose (MTD) of 150 mg per day (Hidalgo et al 2001). The 
most common toxicities were diarrhea (25%–67% depending 
on dose) and rash (59%). The diarrhea was mostly grade 1 
and 2 and improved with anti-diarrhea agents. The cutane-
ous toxicities were mostly on the face and upper trunk and 
of a pustular acneiform type. The rash appeared 1–2 weeks 
post initiation of therapy and subsided by week 4 without 
interruption of the erlotinib. The most common skin biopsy 
ﬁ  nding was a neutriphilic inﬁ  ltration of the dermal layer. 
Patients with skin manifestations had a higher area under the 
curve (AUC) concentration of erlotinib compared to those 
without skin changes. Higher AUC levels did not correlate 
with diarrhea though. The pharmacokinetics of erlotinib was 
not dose dependent and there was no drug accumulation with 
the continuous daily dosing.
The weekly regimen was explored further in patients with 
advanced stage NSCLC with dose escalation of 1200 mg, 
1600 mg, and 2000 mg, but was discontinued due to a low 
response rate (5%) (Milton et al 2006).
Erlotinib as second or third-line 
therapy in NSCLC
Based on promising results in the phase I studies, as well 
as early encouraging phase II results with the related agent 
geﬁ  tinib (IDEAL 1 and 2) further development proceeded in 
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Figure 1a Structure of erlotinib.
NSCLC (Fukuoka et al 2003; Kris et al 2003). Fifty-seven 
patients with refractory or relapsed stage II or IV NSCLC 
were treated with erlotinib in a phase II single-agent study 
(Perez-Solar et al 2004). Only patients with positive EGFR-
expression on immunohistochemistry (IHC) were included 
and an overall response rate of 12.3% was reported. Interest-
ingly, all the patients who responded developed a rash, as did 
95% of those with stable disease, compared to only 54% of 
those with disease progression. Patients developing a rash 
also had a longer median survival (no rash: 1.5 months; grade 
1:8.5 months; grade 2, 3:19.6 months). Rash was the most 
signiﬁ  cant predictor of survival in multivariate analysis. The 
intensity of EGFR staining, however, did not affect response 
rate or survival.
These encouraging results led to a randomized double-
blind placebo controlled trial (BR.21) in patients with previ-
ously treated NSCLC (Shepherd et al 2005). Patients with 
one or two prior chemotherapy regimens were included. 
The primary endpoint was overall survival (OS) and the 
secondary endpoints included progress-free survival (PFS), 
response rate, response duration, toxicity, and quality of life 
(QoL) which will be discussed later in this review. Interest-
ingly, patients with ECOG performance status of 3 were 
also allowed to participate in this study, a population usually 
excluded from chemotherapy trials. A 2:1 randomization was 
done with erlotinib 150 mg daily versus placebo.
The response rate in BR.21 trial with erlotinib was 8.9% 
with a median response duration of 7.9 months. Similar 
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response rates have been reported for the chemotherapy 
drugs approved in this setting, docetaxel and pemetrexed 
(Shepherd et al 2000; Fossella et al 2000; Hanna et al 2004). 
In the BR.21 study, the response rates were even higher 
in the following patients: women (14.4%), never-smokers 
(24.7%), those with Asian ethnicity (18.9%), and those with 
adenocarcinoma histology (13.9%). The number of prior 
regimens, age or performance status did not affect response 
rates. Tumors with  10% EGFR positivity by IHC and/or 
activating mutations within the EGFR (discussed below) also 
had a higher response rate. The correlative studies performed 
in the BR.21 study will be discussed later in this review.
As expected, the most common toxicities seen in this 
trial were diarrhea and rash as was seen in the previous 
studies. Dose reductions were carried out in 12% of patients 
due to rash and 5% for diarrhea. Erlotinib was discontinued 
only in 5% of patients due to toxicity. In contrast to most 
cytotoxic agents, grade 3 or 4 neutropenia was not reported 
with erlotinib. In the BR.21 study, pulmonary inﬁ  ltrates and 
pneumonitis (3%) were seen equally in the erlotinib versus 
placebo arm. One patient died on each arm due to pneumo-
nitis which was most likely related to the underlying lung 
cancer and not the drug. This is reassuring, but pneumonitis is 
a known toxicity with this class of agents and caution should 
still be exercised with this drug in patients with underlying 
pulmonary ﬁ  brosis.
Additional toxicity data have been presented on 4423 
patients from Europe who enrolled on an expanded access 
open label trial of erlotinib (TRUST). Rash and diarrhea 
remain the predominant toxicities with a rate of serious 
treatment related adverse events of only 5%. Rash was seen 
in 70% of patients, by 84% of the time it was grade 1 or 2. 
Only 14% of patients required dose reductions (Gatzemeier 
et al 2007a).
The median PFS with erlotinib versus placebo was 2.2 
months and 1.8 months respectively (adjusted hazard ratio, 
0.61; 95 percent conﬁ  dence interval, 0.51–0.74; p   0.001). 
In multivariate analysis, survival was improved with statisti-
cal signiﬁ  cance in patients with adenocarcinoma histology, 
never smokers or Asian ethnicity. However, sex, age, and per-
formance status did not affect survival. Overall, the median 
OS was 6.7 months in the erlotinib treated patients versus 
4.7 months in the placebo arm. Similar median OS have 
been reported with second-line docetaxel and pemetrexed 
(8.3 months, 7.9 months) (Hanna et al 2004). Currently, 
erlotinib is the only drug approved for third-line therapy in 
NSCLC in the United States and is one of only three drugs 
approved for second line therapy. The agent is also approved 
for use in Europe and Canada based on the encouraging 
results of this trial.
Erlotinib as ﬁ  rst-line therapy 
in NSCLC
For many years the standard of care for ﬁ  rst line treatment of 
NSCLC has been chemotherapy doublets. Multiple trials have 
looked for ways to improve the 8–10 month median survival 
usually seen. These studies included different chemotherapy 
combinations of two and three drugs and the additional of 
“targeted” agents to chemotherapy combinations. As epito-
mized in the ECOG 1594 trial of 4 different platinum doublets 
which all had the same response rate and overall survival, a 
plateau in chemotherapy efﬁ  cacy with doublet regimens has 
been reached (Schiller et al 2002). Additionally no triplet 
regimens have been shown to be superior in terms of survival 
(Delbaldo et al 2004). Trials with targeted agents have also 
failed to show a beneﬁ  t when added to doublet chemotherapy 
(Herbst et al 2005a; Giaconne et al 2004). The exception to 
this is ECOG E4599 which compared chemotherapy alone 
with chemotherapy plus bevacizumab (Avastin®; Genentech, 
So San Francisco, CA, USA) (Sandler et al 2006a). Patients 
received carboplatin plus paclitaxel with or without the 
monoclonal anti-VEGF antibody. The response rates and 
the median OS were improved in the bevacizumab arm. 
This study resulted in the approval of bevacizumab in com-
bination with chemotherapy for ﬁ  rst-line therapy in patients 
with advanced NSCLC in the United States. However, 15 
treatment related deaths were reported in the bevacizumab 
arm including 5 patients with pulmonary hemorrhage. A con-
ﬁ  rmatory trial in Europe (AVAiL) has been reported to show 
an improvement in PFS with the addition of bevacizumab to 
cisplatin and gemcitabine, but the overall survival data have 
not yet been presented (Manegold et al 2007). Toxicity was 
less severe than what was seen in E4599, though bleeding 
remains a concern. Bevacizumab plus a platinum doublet is 
still the only triplet regimen shown to improve survival in 
the ﬁ  rst-line treatment of advanced NSCLC.
As with other targeted agents, when erlotinib was added 
to ﬁ  rst-line chemotherapy, the results were disappointing. 
Despite encouraging preclinical studies with the combination 
of erlotinib and chemotherapy (Gumerlock et al 2003), two 
large randomized trials of erlotinib plus ﬁ  rst-line doublet 
chemotherapy in advanced stage NSCLC showed no advan-
tage with the addition of the erlotinib. The TRIBUTE trial 
was conducted in treatment naïve patients with advanced 
or metastatic NSCLC who were treated with chemotherapy 
plus erlotinib versus placebo (Herbst et al 2005a). Patients Biologics: Targets & Therapy 2007:1(4) 338
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received paclitaxel 200 mg/m2 followed by carboplatin 
(AUC 6) every 21 days for 6 cycles plus erlotinib at 150 
mg/day versus placebo. With more than a thousand patients 
treated there was no difference in median survival, time to 
progression, or objective response rates. In addition, there 
was no correlation between EGFR expression level and 
outcome. However, the response rates were higher in never 
smokers treated on the erlotinib arm (30% vs 11%). These 
patients also had an improved survival when treated with 
chemotherapy and erlotinib (22.5 months) versus placebo 
(10.1 months) which was independent of tumor histology.
Another placebo controlled randomized study (TALENT) 
was reported in treatment naïve unresectable stage III or IV 
NSCLC (Gatzemeier et al 2007b). In this study, patients 
received 6 cycles of cisplatin (80 mg/m2 d1) and gemcitabine 
(1250 mg/m2 d1, 8) plus erlotinib (150 mg daily) or placebo 
with responding patients continuing on study drug until pro-
gression. The pharmacokinetics of gemcitabine or cisplatin 
was not altered by erlotinib. Again, there was no difference 
in response rates, overall survival, time to progression, and 
time to symptom progression with 1172 patients enrolled. 
The exception to this was a survival beneﬁ  t seen in a subset 
analysis never smokers. Based on these two randomized 
trials, erlotinib has no role in ﬁ  rst-line therapy when given 
concurrently with chemotherapy in an unselected patient 
population.
Various explanations have been proposed for the nega-
tive results reported in the TALENT and TRIBUTE trials. 
Gumerlock argues that since erlotinib results in G1 arrest, 
the efﬁ  cacy of chemotherapy is affected due to its reliance 
on mitosis (Gumerlock et al 2003). To get around this effect 
investigators have looked at sequencing erlotinib and chemo-
therapy so that cells are released from G1 arrest in time for 
chemotherapy to be efﬁ  cacious. A phase I study evaluating 
the sequential administration of docetaxel and erlotinib has 
been completed (Davies et al 2005). There were two arms 
on this study with arm A receiving docetaxel (70–75 mg/m2) 
every 21 days followed by erlotinib (600–800 mg) weekly on 
days 2, 9, 16. The MTD was docetaxel 70 mg/m2 and erlo-
tinib 600 mg. In arm B, patients were treated with docetaxel 
(70–75 mg/m2) every 21 days and erlotinib (150–300 mg) 
daily on days 2–16. The MTD in this arm was docetaxel 70 
mg/m2 and erlotinib 200 mg. Responses were seen in 8 of 22 
NSCLC patients (4 PR, 4 MR). Phase II studies are ongo-
ing according to arm B. At an updated presentation in 2007 
the response rate with this approach was 38% (2 CR and 12 
PR of 39 patients) with a time to progression of 5.6 months 
and median survival not yet reached (Davies et al 2007). 
A similar trial design with pemetrexed is ongoing. With 
these encouraging results, the role of erlotinib in combination 
with chemotherapy for ﬁ  rst-line therapy may be re-addressed 
utilizing this pulse sequencing approach.
A randomized phase II trial presented at the ASCO 
meeting this year evaluated different strategies of pulse dose 
erlotinib (either 150 mg or 1500 mg) given for just 2 days 
prior to chemotherapy or at the higher dose for 2 days after 
chemotherapy (Riely et al 2007). This approach was no bet-
ter than the TRIBUTE trial with response rates ranging from 
18% to 35% and median overall survival of 15 months.
Erlotinib in combination with ﬁ  rst-line chemotherapy is 
also under investigation in select populations such as never-
smokers. The Cancer and Leukemia Group B (CALGB) trial 
30406 is an ongoing randomized phase II study evaluating 
erlotinib alone or in combination with carboplatin/paclitaxel 
as ﬁ  rst-line therapy for light and never smokers. ECOG is 
also considering a trial in this population which would consist 
of administering carboplatin and paclitaxel with or without 
erlotinib (and including bevacizumab for patients eligible 
for bevacizumab). Both of these trials also include extensive 
correlatives evaluating EGFR IHC, EGFR mutation status, 
EGFR expression by FISH, KRAS mutation status, and also 
proteomic analysis.
Currently, the combination of erlotinib plus ﬁ  rst-line 
chemotherapy should be considered experimental and 
focused on determining patient selection criteria or improved 
sequencing. Unfortunately, like the studies of erlotinib plus 
chemotherapy in non-selected populations, studies of single 
agent erlotinib ﬁ  rst-line have been disappointing to date. The 
recently completed ECOG 3503 trial of ﬁ  rst-line erlotinib 
sought to gather additional data for patient selection (Kolesar 
et al 2007). This study enrolled 118 eligible patients to 
receive ﬁ  rst-line therapy with erlotinib for advanced stage 
NSCLC. Patients were started at 150 mg daily and gradually 
escalated every 2 weeks to a maximum dose of 250 mg daily 
as tolerated with rash as the primary criteria. The response 
rate was 7% with a median survival of 7.9 months. Rash did 
correlate with improved survival, but not statistically.
A phase II study evaluating the role of single agent 
erlotinib in ﬁ  rst-line therapy for patients with stage IIIB/IV 
NSCLC enrolled 53 patients and reported an ORR of 22.7% 
and a disease control rate of 52.8% (Giaccone et al 2006). 
The median duration of response for those responding was 
11 months. Never smokers responded better with a 1 year 
OS of 54% and a median survival of 13 months. The median 
overall survival for all patients on the trial was 13 months. As 
stated previously, the median OS in E 4599 was 12.3 months Biologics: Targets & Therapy 2007:1(4) 339
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with the chemotherapy and bevacizumab combination. In the 
single agent erlotinib study, the following factors correlated 
with a better median survival: grade 2/3 skin toxicity (19.7 
months vs 2.7 months in grade 0), bronchioloalveolar car-
cinoma (BAC) or adenocarcinoma, age  70 years, positive 
response to erlotinib, EGFR mutation (20 mo vs 12.6 mo 
in wild type), and KRAS wild type (20 mo vs 5.7 mo in 
mutants). Higher responses were seen in adenocarcinoma 
and BAC histologies and never smokers. These results were 
replicated by a second trial reported by Jackman.
The Jackman trial focused on elderly patients and 80 
patients  70 years of age with advanced or metastatic 
NSCLC were treated with ﬁ  rst-line daily erlotinib 150 mg 
(Jackman et al 2007) until disease progression. Toxicities 
were mainly grade 1 or 2 rash and diarrhea. Twelve patients 
(15%) were removed from study secondary to side effects 
including one toxic death. The disease control rate was 
51% including 10% PR. The median survival of all patients 
was 10.9 months with a 2 year OS of 19%. Interestingly, 
all patients with EGFR mutation had disease control with 
prolonged time to progression and OS. EGFR mutation 
was more common in patients who had a  15 pack year 
history of smoking. Six patients with KRAS mutation did 
not respond and had a poor outcome. No patient had both 
KRAS and EGFR mutation. The other factor correlating 
with response and better survival was the development of 
an erlotinib-related rash.
More recently, a randomized phase II trial has been 
reported comparing ﬁ  rst-line single agent erlotinib (n = 52) 
with carboplatin/paclitaxel (n = 51) chemotherapy in patients 
with advanced stage NSCLC with ECOG performance 
status of 2 (PS 2) (Lilenbaum et al 2006). The response 
rates with erlotinib versus chemotherapy were 2% and 12% 
respectively. The median OS was better with chemotherapy 
as was improvement in chest pain. However, there was no 
signiﬁ  cant difference in the other QoL parameters between 
the two groups. Interestingly, none of 9 patients in the erlo-
tinib arm had an EGFR mutation, whereas, 3 of 11 had the 
KRAS mutation. The number of patients tested is too small 
for any meaningful conclusions about the relationship of 
these mutations with the outcome of this study. Overall, this 
randomized phase II study suggests that chemotherapy can 
be given safely to patients with PS of 2 and that the response 
rates are better than single agent erlotinib.
The data with ﬁ  rst-line single agent erlotinib are limited, 
and it should not be considered a standard approach. Ongo-
ing trials in selected populations either felt to have a higher 
probability of responding, or at increased risk for toxicity 
are clearly warranted. There are multiple phase II studies 
ongoing and few reported in patients selected on clinical 
criteria (never-smokers) and or molecular criteria (EGFR 
mutations, or EGFR over-expression) (Inoue et al 2006; Paz-
Ares et al 2006; Sequist et al 2007). Additionally, a phase 
III European trial of over 300 patients randomizes female 
never-smokers to either chemotherapy or erlotinib as a single 
agent as ﬁ  rst-line therapy.
Moving erlotinib into other stages 
of disease
This review focuses on erlotinib in advanced stage NSCLC, 
but the drug is also being investigated in earlier stages of 
disease. An ongoing adjuvant trial, RADIANT, is open 
world-wide to patients with stage I-IIIA resected NSCLC 
who have evidence of EGFR over-expression by either IHC 
or FISH. Eligible patients will be randomized to either 2 
years of erlotinib or observation, after completion of adjuvant 
chemotherapy at the discretion of the treating physician. 
Neo-adjuvant therapy trials with erlotinib have also been 
done, primarily evaluating molecular changes in the tumor 
that predict for response.
Further exploration of the drug in locally advanced 
disease is proceeding with caution given the surprising 
and disappointing results of SWOG 0023 with geﬁ  tinib. 
SWOG 0023 enrolled patients with stage IIIB NSCLC and 
treated them with chemotherapy and radiation, followed by 
consolidation chemotherapy, followed by a randomization 
to geﬁ  tinib or placebo (Kelly et al 2007). The surprising 
results showed reduced survival with the addition of the 
geﬁ  tinib, primarily due to excess cancer death in that arm. 
These results have clearly reduced enthusiasm for further 
study of EGFR-TKIs after completion of chemotherapy and 
radiation for locally advanced disease. They speak to caution 
in the adjuvant setting, but the RADIANT trial remains an 
important study.
Quality of life
One of the major advantages of erlotinib over chemotherapy 
is quality of life (QoL). Improvement in QoL was evalu-
ated in the BR.21 trial (Shepherd et al 2005) by using the 
European organization for research and treatment of cancer 
(EORTC) QLQ-C30 QoL questionnaire and the QLQ-LC13 
lung module (Bezjak et al 2006). The endpoint of QoL 
analysis was to determine the time to worsening of cough, 
dyspnea, and pain. Patients who were receiving erlotinib had 
a longer time to deterioration of symptoms and a 34%–44% 
improvement in lung cancer associated symptoms. The QoL Biologics: Targets & Therapy 2007:1(4) 340
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improved by 9% (p   0.0001) in patients who were receiving 
erlotinib.
QoL was also measured in the initial phase II trial with 
the drug and the incidence of lung cancer symptoms includ-
ing fatigue, cough, and dyspnea decreased after erlotinib 
was initiated in the 57 patients on the study (Perez-Soler 
et al 2004).
Predictors of response to erlotinib
We are moving into an era of “personalized medicine” with 
the hope that we may be able to predict ahead of time which 
agents will be best for each individual patient. Though prog-
ress is being made with traditional chemotherapeutic agents, 
we are much closer to this reality with the newer targeted 
agents, particularly erlotinib. Detection of EGFR expression 
and speciﬁ  c mutations within the gene allow for selection of 
patients most likely to beneﬁ  t from the drug.
EGFR expression
EGFR expression has been detected in the bronchial epi-
thelium of heavy smokers at risk of developing lung cancer 
(Franklin et al 2002). The degree of EGFR expression 
can be evaluated by immunohistochemistry (IHC) and the 
EGFR gene copy number by ﬂ  uorescent in situ hybridization 
(FISH). Hirsch and colleagues evaluated 183 NSCLC tumor 
samples by IHC and FISH (Hirsch et al 2003). EGFR over-
expression was observed in 62% of patients with NSCLC 
with squamous cell carcinoma the most common histology 
associated with high expression. Expression levels did not 
correlate with survival, stage, age, gender, or smoking his-
tory. Well differentiated tumors had a higher level of EGFR 
expression compared to poorly differentiated tumors.
The EGFR gene is on chromosome 7p12 and Hirsch 
found 4 major FISH patterns in the 183 tumor samples 
tested (Hirsch et al 2003). Low levels of EGFR expression 
by IHC was associated with the following 2 FISH patterns: 
balanced disomy (equal EGFR gene and chr 7) and balanced 
trisomy (similar low level gains in both EGFR gene and 
chr 7). High levels of EGFR expression was associated with 
balanced polysomy (similar high level gains in EGFR gene 
and chr 7) and EGFR gene ampliﬁ  cation (unbalanced gain 
of EGFR gene). These FISH patterns did not correlate with 
patient characteristics. A low gene copy was associated with 
non-squamous cell histology.
In another study utilizing FISH technology, 42 small 
NSCLC samples from geﬁ  tinib treated patients were examined 
for EGFR by FISH, and for mutations in EGFR (Daniele 
et al 2007). DNA was extracted and sequenced by PCR. 
EGFR was ampliﬁ  ed and evaluated for mutational status 
and gene copy number. Seven of 7 patients (100%) with 
EGFR mutation (6 in Exon 19 and 1 in Exon 21) responded 
to geﬁ  tinib compared to 5 of 35 (14%) without the muta-
tion (p   0.0001). The FISH analysis was able to detect an 
increase in the EGFR gene and number of chromosome 7 
copies which correlated with speciﬁ  c EGFR mutations. In 
another geﬁ  tinib study, 102 NSCLC tumor samples were 
evaluated for number of gene copies by FISH (Cappuzzo 
et al 2005). EGFR gene ampliﬁ  cation and a high polysomy 
was associated better response, TTP and OS (18.7 months vs 
7 months). In addition, EGFR mutations, by DNA sequenc-
ing, were shown to be related to a better response and TTP 
but not OS.
In a recent report of patients with BAC, gene ampliﬁ  ca-
tion in combination with EGFR mutation (exon 19, 21) was 
shown to a strong predictor of response to erlotinib (Miller 
et al 2006). Patients with both EGFR activating mutations 
and gene ampliﬁ  cation had a 90% response rate and a median 
OS of 35 months. In comparison, patients with no mutations 
and no gene ampliﬁ  cation had a 4% response rate and median 
OS of 15 months.
In the BR.21 study, EGFR expression in the erlotinib 
treated group was associated with a better response without 
a survival advantage (Tsao et al 2005). Thus EGFR expres-
sion by IHC alone does not seem to be useful in predicting 
survival after erlotinib therapy. The FISH analysis from 
BR.21, however, did show a striking beneﬁ  t in survival for 
the EGFR FISH positive patients versus the FISH negative 
patients (p = 0.002).
More recently, it has been suggested that NSCLC tumors 
from Western populations negative for EGFR by FISH and 
IHC do not respond to geﬁ  tinib (Hirsch et al 2007). In this 
study, patients with EGFR positive tumors by both FISH 
and IHC had a median survival of 21 months compared to 6 
months with FISH and IHC negative tumors. Similar results 
were found in the ONCOBELL trial treating NSCLC patients 
who had EGFR positive tumors with geﬁ  tinib (Cappuzzo 
et al 2007). FISH is a more accurate diagnostic modality for 
EGFR-TKI patient selection, than IHC. The recent TRUST, 
open access European erlotinib study, also conﬁ  rmed the 
increased beneﬁ  t of FISH versus IHC. Patients with EGFR 
IHC positive tumors had a HR for survival of 0.75, p = 0.1, 
but those with FISH positive tumors had a HR for survival 
of 0.53, p = 0.02 (Schneider et al 2007). There was high 
concordance with EGFR positivity by FISH and IHC on 
this study though (93%) (Laack et al 2007). The ability of 
EGFR over-expression by FISH analysis to predict response Biologics: Targets & Therapy 2007:1(4) 341
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to EGFR-TKIs has been clearly demonstrated but the debate 
about the relative strength of FISH analysis versus EGFR 
mutational analysis is ongoing.
EGFR mutation
The phenomenal responses seen in a small number of patients 
led investigators to sequence EGFR and several activating 
mutations have now been identiﬁ  ed. This was initially seen 
in 2004 when two groups simultaneously published small 
series of patients with excellent responses to geﬁ  tinib with 
speciﬁ  c mutations in EGFR. Paez and colleagues examined 
tumors from 119 Japanese and Caucasian NSCLC patients 
treated with geﬁ  tinib (Paez et al 2004). Somatic mutations 
were found in 5 of 5 responders and 0 of 4 non-responders 
(p = 0.0027). Most mutations were found in Japanese females 
with adenocarcinoma. In a report by Lynch, 8 of 9 geﬁ  tinib 
responders had mutations of the TK domain compared to 0 
of 7 non-responders (Lynch 2004). All amino acid deletions 
were seen in exon 19 while substitutions were in exons 18 
and 21. Tumors with these somatic mutations have a better 
prognosis (Bunn et al 2002) and are normally associated 
with never smokers, Asian race, female gender, and adeno-
carcinoma histology. In one study, 7 of 15 non-smokers had 
mutations compared to 4 of 81 smokers (p = 0.0001) (Pao 
et al 2004). Moreover, EGFR mutations have been reported 
to be more common in light smokers (Jackman et al 2006; 
Sequist et al 2007). In one study, 68 of 278 (24%) patients 
had EGFR somatic mutations (Sequist et al 2007). The pres-
ence of the mutation correlated with smoking history with 
a 5% decrease in chance of a mutation with each pack-year 
smoking history. The EGFR mutated tumors responded better 
to EGFR-TKI but not to chemotherapy.
In the BR.21 mutational analysis study, 40 of 177 (23%) 
samples were positive for mutations in exons 18–21 (Tsao 
et al 2005). EGFR mutations were found at varying levels 
in the following subgroups: males (22%), females (24%), 
Asians (50%), non-Asians (21%), never smokers (31%), 
and adenocarcinoma (28%). In this trial surprisingly, the 
presence of mutations did not correlate with response or 
survival even in patients with classic exon 19 or 21 muta-
tions. This was attributed to low number of patients positive 
for mutations in this study. There was a trend towards better 
response rate in those with mutations, but not of statistical 
signiﬁ  cance. In another study, all patients with EGFR muta-
tions had disease control with prolonged time to progression 
and OS (Jackman et al 2007). These results were also seen 
in a study by Cappuzzo, except that the survival advantage 
was not statistically significant (Cappuzzo et al 2005). 
There is a lot to be learned about these mutations especially 
since the BR.21 investigators found 24 novel mutations not 
previously described. The majority of activating mutations 
are of 3 dominant types, deletions in exon 19, insertions in 
exon 20 or a single point mutation L858R. Another report 
conﬁ  rms that E746_A750 exon 19 deletion and L858R mis-
sense mutation to be the most common EGFR mutations 
(Janne et al 2005). It is important to note that the tyrosine 
kinase domain is encoded by exons 18–24 and the EGFR 
mutations have only been found in this domain (Paez et al 
2004; Pao et al 2004).
More recent data have focused on patients with known 
mutations in EGFR who initially respond and subsequently 
become resistant to erlotinib. Secondary mutations have 
been identiﬁ  ed in some of these patients, predominantly in 
the T790M location (Vikis et al 2007). Over-expression of 
MET has also been identiﬁ  ed in other patients who initially 
responded to EGFR-TKI and subsequently became resistant 
(Engleman et al 2007). Several novel TKIs are in develop-
ment to overcome resistance in this setting.
Other genes
KRAS is downstream to EGFR and its mutation has been 
shown to affect the efﬁ  cacy of erlotinib. In the TRIBUTE 
trial, DNA was extracted from tumor samples and the EGFR 
exons 18–21 and KRAS exon 2 were ampliﬁ  ed (Eberhart et al 
2005). Only 12.7% of tumors had EGFR mutations which 
translated into a better response rate with the chemotherapy 
and erlotinib combination. In this study, EGFR mutation 
was found to be a favorable prognostic factor in patients 
with NSCLC. The overall response rate with chemotherapy 
and erlotinib was 53% compared to 21% with chemotherapy 
alone. However, patients with the KRAS mutation did poorly 
with the addition of erlotinib in this trial. In a BAC study, 
KRAS mutation was associated with resistance to erlotinib 
(Miller et al 2006). KRAS mutations and EGFR mutations 
are generally mutually exclusive (Tam et al 2006; Bae et al 
2007; Mounawar et al 2007). The recent TRUST open access 
erlotinib study in Europe also showed the KRAS was asso-
ciated with decreased survival, though without statistical 
signiﬁ  cance (Schneider et al 2007).
Phosphorylated MAP kinase is also involved in the EGFR 
signaling pathway had is under investigation as well as a 
predictor of response to EGFR-TKIs.
Proteomic analysis
A recent publication assesses the use of mass spectrom-
etry proteomic analysis of response of NSCLC patients to Biologics: Targets & Therapy 2007:1(4) 342
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erlotinib and geﬁ  tinib (Taguchi et al 2007). The study used 
serum from NSCLC patients prior to therapy with erlotinib 
or geﬁ  tinib and found patterns predictive of good or poor 
outcome. These results were validated in different cohorts 
with testing at two separate institutions with good concor-
dance. This technology will be the basis for an ECOG trial 
currently in development.
Cutaneous toxicity
Cutaneous toxicity is common in patients treated with erlo-
tinib. Dose reductions and discontinuation of therapy are 
needed in some patients. There are several theories on the 
etiology of these skin reactions. EGFR is expressed on the 
keratinocytes, sebaceous gland cells, and the outer sheath of 
hair follicles (Lee et al 2004). EGFR inhibition can result in 
follicle occlusion and acneiform eruption with inﬂ  amma-
tion (Journagan 2006). Individuals normally present with a 
papulopustular rash affecting the face and the upper trunk 
occurring in the ﬁ  rst weeks of therapy (Luu et al 2007). 
Topical antibiotics are routinely used, with escalation to 
oral antibiotics as necessary even though there has never 
been an association with any infectious organism. Topical 
steroids are also utilized, though with controversy. The rash 
normally clears with these measures even with continuation 
of erlotinib therapy. In addition, the rash has been reported 
to worsen with photoexposure and patients should be advised 
to use sunscreen (Luu et al 2007). There are currently no 
formal guidelines available for the management of cutane-
ous toxicity related to erlotinib use. A recent presentation at 
ASCO (Jatoi et al 2007) explored the use of tetracycline to 
alleviate the rash and found that though the rate of develop-
ment of rash was not reduced by tetracycline, the severity 
was diminished with this agent.
Erlotinib metabolism and drug 
adjustments
Cytochrome P450-3A (CYP3A) is one of the major sub-
families of the CYP450 family of genes present in the liver 
(Guengerich 1995). CYP3A is composed of the following 
isoforms: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. 
These genes are responsible for the metabolism of up to half 
of drugs used in humans. Of note, genetic variations have 
been described which may cause altered drug metabolism 
(Eichelbaum and Burk 2001).
CYP3A4 is the major isoform responsible for erlotinib 
metabolism (Li et al 2007). Caution should be exercised 
when combining erlotinib to CYP3A4 inhibitors or inducers 
as this may increase or decrease the erlotinib AUC (Table 1). 
A dose reduction in erlotinib should be considered if a patient 
is on a CYP3A4 inhibitor as an increase in toxicity could be 
experienced due to an increase in the level of erlotinib.
Smoking also dramatically increases activity of CYP1A2, 
another enzyme involved in erlotinib metabolism and this 
is hypothesized to be one reason for lack of efﬁ  cacy of the 
drug in smokers, due to increased clearance (Li et al 2007). 
Ongoing trials are exploring dose escalation of erlotinib in 
smokers to see if this can be overcome.
Novel drug combinations
There are many novel/targeted agents currently in clinical 
trials in combination with erlotinib (Table 2). Completed 
phase I/II studies are discussed below.
Bevacizumab was combined with erlotinib in a phase 
I/II study in patients with relapsed non-squamous NCSLC 
(Herbst et al 2005b; Sandler et al 2006b). Blocking the 
EGFR inhibits the synthesis of angiogenic factors including 
vascular endothelial growth factor (VEGF) which in turn 
prevents endothelial response to VEGF with the addition of 
bevacizumab. Furthermore, there is some evidence to suggest 
that bevacizumab inhibits the EGFR autocrine function (Petit 
et al 1997; Hirata et al 2002). There was no DLT reported in 
the phase I portion and 34 patients were treated at the phase II 
doses with erlotinib 150 mg daily and bevacizumab 15 mg/kg 
every 21 days. The most common toxicities were diarrhea, 
rash, hematuria, and proteinuria with no treatment related 
deaths. There was a 20% PR and a 65% SD with a median OS 
of 12.6 months and a PFS of 6.2 months. Nine tumors were 
tested for EGFR mutations in exons 19–21 and 23 and only 
2 had the mutation (1 PR and 1 SD). Conﬁ  rmation of these 
exciting preliminary results is being sought in two interna-
tional phase III trials, ATLAS, and Beta. The ATLAS trial 
(N = 1150) is a randomized double-blind, placebo-controlled 
Table 1 CYP3A4 inhibitors and inducers (concise list)
Inhibitors Inducers
Ketoconazole Rifabutin
Atanazavir Rifapentin
Clarithromycin Phenytoin
Indinavir Carbamazepine
Itraconazole Phenobarbitol
Nefazodone  St. John’s wort
Nelﬁ  navir  Rifampicin
Ritonavir
Saquinavir
Telithromycin
Troleandomycin
Voriconazole
Grape juiceBiologics: Targets & Therapy 2007:1(4) 343
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phase IIIb trial that compares bevacizumab with or without 
erlotinib after completion of ﬁ  rst-line chemotherapy with 
bevacizumab for advanced NSCLC (non-squamous). The 
Beta trial (N = 650) randomizes patients requiring second-line 
therapy to erlotinib with or without bevacizumab.
These promising results with dual EGFR/VEGFR inhibition 
have also been seen with single drugs that target both receptors. 
The one furthest in development is ZD6474 (vandetanib). This 
compound has been directly compared to geﬁ  tinib in phase II 
testing with favorable results (Natale et al 2006). This has led 
to an ongoing trial of the compound versus erlotinib.
Erlotinib is also being studied in combination with 
radiation, both in the thorax and for central nervous system 
metastasis.
Future direction
Erlotinib has a clear role in second or third-line treatment of 
NSCLC. The decision of when to administer (either second- 
or third-line) can be challenging. Certain patients, such as 
never-smokers and those with known EGFR mutations, will 
obviously be offered the drug second-line (if they were not 
given it ﬁ  rst-line as part of a trial). For those patients with-
out favorable clinical or molecular predictors of response 
though, it is difﬁ  cult to know if erlotinib is as efﬁ  cacious 
as either docetaxel or pemetrexed. The ongoing TITAN 
trial will hopefully answer this question. This phase III trial 
randomizes patients to receive either erlotinib or docetaxel 
or pemetrexed. Several of the ongoing randomized studies 
with erlotinib are listed in Table 3.
The other major question in second line therapy is when to 
start treatment. Older trials had shown no advantage to con-
tinuing beyond 4–6 cycles of standard doublet chemotherapy, 
but more recent data, bring back the question of whether we 
should be offering second line therapy sooner (Fidias et al 
2007). The ongoing SATURN study randomizes patients 
to either placebo or erlotinib after completion of ﬁ  rst-line 
chemotherapy and will hopefully help further in resolving 
this controversy. The ATLAS trial also randomizes patients 
to receive either erlotinib or placebo after completion of 4 
cycles of a platinum based regimen, but with the addition of 
bevacizumab to both arms.
Table 2 Selected targeted drug combinations with erlotinib in 
clinical trials
a. Anti-angiogenesis
 ADH-1
 AVE0005
 Bevacizumab
 Volociximab
 Vandetanib
b. EGFR  inhibitors
 Cetuximab
 Vandetanib
c. Multiple  receptor  TKI
 Sorafenib
 Sunitinib
  Vandetanib (ZD 6474)
 Dasatinib
d. Triple  combinations
  Bevacizumab and cetuximab
  Bevacizumab and docetaxel
  Bevacizumab and pemetrexed
  Bevacizumab and temsirolimus
  Carboplatin and docetaxel
  Cisplatin and gemcitabine
e. Miscellaneous
  Bexarotene (BATTLE trial)
 Temsirolimus  (CCI-779)
 RAD001
 Perifosine
 Promune  (PF-3512676)
 hydroxychloroquine
 Bortezomib
 Celecoxib
 Digoxin
 Docetaxel
 Enzastaurin
 Fulvestrant
 Vorinostat  (SAHA)
 Hydrochloroquine
 Pemetrexed
 Perifosine
 Promune
 Vorinostat
 Satraplatin
Table 3 Ongoing phase III trials with erlotinib
ο  RADIANT – Erlotinib or placebo following complete resection
  and adjuvant chemotherapy for resected stage I-IIIA
  NSCLC for patients whose tumors over-express EGFR either
  by IHC or FISH
ο  SATURN – Erlotinib or placebo following 4 cycles of carbo-
  platin/paclitaxel for advanced stage NSCLC
ο  ATLAS – Erlotinib or placebo plus bevacizumab following 4
  cycles of doublet chemotherapy plus bevacizumab for
  advanced stage NSCLC
ο  Beta – Erlotinib plus placebo versus erlotinib plus bevaci-
  zumab for second-line therapy of advanced stage NSCLC
ο  TITAN – Erlotinib versus docetaxel or pemetrexed for
  second-line therapy of advanced stage NSCLC
ο  Erlotinib versus vandetanib (ZD6474) for advanced stage NSCLC
ο  Erlotinib versus chemotherapy in women never smokers as
  ﬁ  rst-line therapy for advanced NSCLC
ο  Erlotinib or placebo after completion of concurrent
  carboplatin/paclitaxel/radiation for inoperable stage III NSCLCBiologics: Targets & Therapy 2007:1(4) 344
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Further investigation of erlotinib in ﬁ  rst-line therapy, 
either alone or in combination with chemotherapy is also 
ongoing. Ideally we will be able to select, based on markers 
such as EGFR expression by FISH, and mutational analy-
sis, who should receive erlotinib and at what point in their 
therapy. We are certainly closer to this step in personalized 
cancer therapy than we are in predicting the same issues with 
conventional chemotherapy.
The best therapy for those who have initially responded 
to erlotinib and have subsequently lost their response either 
through development of the T790M mutation or another resis-
tance mechanism, remains another area of active research. 
Hopefully at least one of the newer TKIs in development 
will help in this situation.
Conclusions
EGFR-TKIs belong to a new class of targeted agents that 
have shown to be beneficial in patients with advanced 
NSCLC. Erlotinib is currently approved in many countries 
as a single agent for use in the second or third line setting for 
this disease. Though response rates in the general population 
are no better than those seen with standard chemotherapy, a 
certain group of patients have striking and durable responses. 
Some clinical characteristics help predict response, including 
never-smokers, women and those of East Asian ethnicity. 
These characteristics correlate with activating mutations in 
the EGFR gene. Higher gene copy number as predicted by 
FISH analysis is also correlated with better survival with 
treatment with this agent. A survival beneﬁ  t has been dem-
onstrated in an unselected patient population as well though, 
in the landmark BR.21 trial. Ongoing trials seek to improve 
therapy with this agent further with combination regimens 
and better understanding of predictors of beneﬁ  t with therapy. 
Though we are not yet in an era of personalized medicine, 
we are close with erlotinib which has become a crucial part 
of the lung cancer arsenal.
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